Cannabis News & Analysis
2 articles
Market Mood
Trump Administration Moves Cannabis to Schedule III for Research Benefits
The Trump administration has proposed reclassifying cannabis from Schedule I to Schedule III, which would allow greater scientific research into its medical applications. This change does not legalize cannabis federally but provides clarity for researchers and patients. The Department of Justice also stated that companies can now deduct expenses under IRS Code Section 280E, potentially improving financial situations for cannabis firms. This policy shift may positively impact companies such as Tilray (TLRY), which is enhancing its medical cannabis segment and expects increased interest from pharmaceutical partnerships.
Read More
White House Marijuana Controls Easing Expected Soon
The U.S. Department of Justice (DOJ) is expected to ease marijuana controls as soon as Wednesday. This follows news that President Trump may soon reclassify marijuana to a safer drug category. The reclassification could have significant implications for cannabis companies and the broader market. Analysts are evaluating the potential effects on trading volumes and stock prices of cannabis-related firms.
Read More